EFFECTS OF ALPRAZOLAM ON GLUCOSE REGULATION IN DIABETES - RESULTS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

被引:43
作者
LUSTMAN, PJ
GRIFFITH, LS
CLOUSE, RE
FREEDLAND, KE
EISEN, SA
RUBIN, EH
CARNEY, RM
MCGILL, JB
机构
[1] WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA
[2] DEPT VET AFFAIRS MED CTR, ST LOUIS, MO USA
关键词
D O I
10.2337/diacare.18.8.1133
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To determine the effects of alprazolam on glucose regulation in anxious and nonanxious patients with poor glycemic control and establish whether regulatory benefits are related to anxiolytic effects of the medication. RESEARCH DESIGN AND METHODS - Fifty-eight patients with poor glycemic control, 16 (27.6%) of whom had a symptomatic generalized anxiety disorder, were entered into a randomized, double-blind, placebo-controlled, 8-week trial using alprazolam (up to 2 mg/day) as the active agent. Generalized anxiety disorder was determined in accordance with Diagnostic and Statistical Manual of Mental Disorders criteria, and anxiety symptoms were measured using the Hopkins Symptom Checklist. Glycated hemoglobin levels were used to determine glucose regulation. Compliance behavior was assessed using glucometers and medication monitors equipped with electronic memory. RESULTS - A statistically significant reduction in glycated hemoglobin level was observed in patients treated with alprazolam compared with those receiving placebo (-1.1 vs. -0.3%, P = 0.04). This treatment effect was not a function of differences in compliance behaviors. Anxiety symptoms decreased in both alprazolam- and placebo-treated patients with generalized anxiety disorder, but reduction in glycated hemoglobin level was not dependent on alleviation of anxiety. CONCLUSIONS - A short course of alprazolam improved glucose regulation in patients with a history of poor diabetes control. This effect was not directly related to concomitant changes in anxiety. Alprazolam treatment of anxious patients with poorly controlled diabetes may result in decreased anxiety and improved glucose regulation through independent mechanisms.
引用
收藏
页码:1133 / 1139
页数:7
相关论文
共 34 条
[1]  
DEROGATIS LR, 1977, SCL90R ADM SCORING P
[2]  
Eisen S A, 1987, J Compliance Health Care, V2, P131
[3]   THE EFFECT OF PRESCRIBED DAILY DOSE FREQUENCY ON PATIENT MEDICATION COMPLIANCE [J].
EISEN, SA ;
MILLER, DK ;
WOODWARD, RS ;
SPITZNAGEL, E ;
PRZYBECK, TR .
ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (09) :1881-1884
[4]   THE EFFECT OF MEDICATION COMPLIANCE ON THE CONTROL OF HYPERTENSION [J].
EISEN, SA ;
WOODWARD, RS ;
MILLER, D ;
SPITZNAGEL, E ;
WINDHAM, CA .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1987, 2 (05) :298-305
[5]   BENZODIAZEPINES DECREASE THE RELEASE OF [H-3]NORADRENALINE AND OF [H-3]ACETYLCHOLINE IN THE CAT SUPERIOR CERVICAL-GANGLION [J].
FILINGER, EJ ;
ELGOYHEN, AB ;
ADLERGRASCHINSKY, E .
NEUROSCIENCE LETTERS, 1989, 105 (1-2) :195-199
[6]  
FYER AJ, 1987, AM J PSYCHIAT, V144, P303
[7]   EFFECTS OF INTRATHECAL MORPHINE, CLONIDINE, AND MIDAZOLAM ON THE SOMATO-SYMPATHOADRENAL REFLEX RESPONSE IN HALOTHANE-ANESTHETIZED CATS [J].
GAUMANN, DM ;
YAKSH, TL ;
TYCE, GM .
ANESTHESIOLOGY, 1990, 73 (03) :425-432
[8]  
GOLDSTEIN DE, 1986, CLIN CHEM, V32, pB64
[9]  
JONAS JM, 1993, J CLIN PSYCHIAT, V54, P25
[10]   INVITRO AND INVIVO EFFECTS OF THE TRIAZOLOBENZODIAZEPINE ALPRAZOLAM ON HYPOTHALAMIC-PITUITARY-ADRENAL FUNCTION - PHARMACOLOGICAL AND CLINICAL IMPLICATIONS [J].
KALOGERAS, KT ;
CALOGERO, AE ;
KURIBAYIASHI, T ;
KHAN, I ;
GALLUCCI, WT ;
KLING, MA ;
CHROUSOS, GP ;
GOLD, PW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (05) :1462-1471